NVCT · Nuvectis Pharma, Inc.
$19.08
+1.05 (+5.82%)
At close · Jul 21
Market Cap
$510.09M
Shares
26.53M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$19.08
Open$18.10
Day$18.10–19.70
52W$5.55–29.28
Avg vol 30d457K
Short int1.8M · 6.8% float · 2.3d
Short vol50%
Last earningsDec 2, 2025
DataFeb 2022–Jul 2026
Filing10-Q · May 5
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 5, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 17.1 · elevated
Equity put/call 0.65
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+102%
above
Price vs 50-day avg
+30%
above
RSI (14)
55
neutral
MACD trend
Negative
52-week position
57%
mid-range
Momentum
relative strength
1-month return
+15%
trailing
6-month return
+118%
trailing
YTD return
+153%
this year
Relative strength
+110%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $15 › 200d $9 — 50d above 200d
Institutional flow
Distributing
8 of 62 funds reported for Jun 30 · net -53.0K sh shares · +3 new
Insider flow
Accumulating
Net +$1.2M over 90 days · 0% sells
Short interest
Rising
6.80% of float · ▲ +14.9% MoM · 2.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
62 holders — near 3-yr high, broad support
Squeeze score
68
elevated · 0–100
Fundamentals
EPS growth
−19%
Y/Y
Balance sheet
$31.6M
net cash
Quant / Vol
risk profile
Volatility
83%
annualized · 1-yr
Max drawdown
−37%
past year
ATR
9.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+102%
Bullish
Price vs 50-day avg
+30%
Bullish
RSI (14)
55
Neutral
MACD trend
Negative
Bearish
52-week position
57%
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $15 › 200d $9 — 50d above 200d
Institutional flow
Distributing
8 of 62 funds reported for Jun 30 · net -53.0K sh shares · +3 new
Insider flow
Accumulating
Net +$1.2M over 90 days · 0% sells
Short interest
Rising
6.80% of float · ▲ +14.9% MoM · 2.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
62 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $6
Now $19 · 57%
52-wk high $29
vs 200-day avg +102%
vs 50-day avg +30%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NVCT
this stock
Nuvectis Pharma, Inc.
|
$510.09M | +152.7% | — | — | 6.8% |
|
ONC
BeOne Medicines Ltd.
|
$460.58B | +4.9% | +22179.2% | 937.3 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$122.33B | +6.3% | +46.2% | 28.6 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.79B | -12.4% | +20.8% | 16.5 | 3.3% |
|
ARGX
Argenx SE
|
$54.08B | +4.0% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NVCT | +4.3% | +15.4% | +118.1% | +3.8% | +152.7% |
| SPY | -0.5% | +0.5% | +7.6% | +0.2% | +9.7% |
| vs SPY | +4.8% | +14.9% | +110.5% | +3.6% | +143.0% |